NEWSROOM

Aclarion

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Feb 3, 2026

Expands availability of Nociscan in the greater Los Angeles area Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure Supports scalable growth strategy while building data assets critical to payer and provider adoption Broomfield, CO, February 03, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Jan 13, 2026

Debt-Free Balance Sheet With $21.6 Million in Cash BROOMFIELD, Colo., Jan. 13, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million...

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Aclarion Provides 2025 Update and 2026 Corporate Outlook

Jan 8, 2026

Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growth Company aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026 BROOMFIELD, Colo.,...

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Jan 6, 2026

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 BROOMFIELD, Colo., Jan. 06, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion,...

Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Dec 4, 2025

Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine care IJSS publishes over 150 articles annually representing 40+ nations BROOMFIELD, Colo., December 4, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Dec 2, 2025

Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies Strong track record of launching breakthrough technologies across spine, neurosurgery and pain management Strengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S BROOMFIELD, Colo., December 2, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc.,...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Nov 5, 2025

Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan Nociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives Broomfield, CO, November 5, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) -...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 22, 2025

Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., October 22, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference

Oct 13, 2025

Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London, titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D., underscored that disc chemistry is the critical biomarker for diagnosing the leading cause of chronic low back pain Nociscan® combines MR Spectroscopy and proprietary AI algorithms to deliver data-driven insights that inform treatment decisions to improve patient outcomes BROOMFIELD, Colo., October 13, 2025 - PRISM...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers

Oct 1, 2025

BROOMFIELD, Colo., October 1, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its recent presentation at LSI Europe ’25 which is now available to investors and stakeholders. The full presentation is...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial

Sep 25, 2025

Enrollment remains on track with internal interim results expected in Q2 2026 Randomized study to evaluate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., September 25, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Appoints Greg Gould as Chief Financial Officer

Sep 3, 2025

HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity Broomfield, CO, September 3, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts

Aug 5, 2025

Nociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume growth for the first time and expects continued QOQ growth for the remainder of the year Cost-effectiveness analysis demonstrating Nociscan is more effective and less costly than provocative discography published in peer-reviewed journal adding critical evidence in support of payer coverage Pivotal...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Jul 7, 2025

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time Broomfield, CO, July 7, 2025 - PRISM MediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Jun 25, 2025

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Jun 24, 2025

Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think Tank BROOMFIELD, Colo., June 24, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the upcoming State of...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

May 12, 2025

Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”)...

Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Aclarion Welcomes Advocate Health as CLARITY Trial Site

May 5, 2025

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Press Audio: BROOMFIELD, Colo., May 05, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 29, 2025

Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries Listen: Broomfield, CO, April 29, 2025 – PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Apr 23, 2025

Broomfield, CO, April 23, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET. Brent Ness, Chief Executive Officer of Aclarion, will...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 21, 2025

Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% Listen: BROOMFIELD, Colo., April 21, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Apr 9, 2025

Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 Broomfield, CO, April 9, 2025 - PRISM MediaWire -Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Apr 2, 2025

MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica Broomfield, CO, April 2, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its Nociscan...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Announces Reverse Stock Split

Mar 26, 2025

BROOMFIELD, Colo., March 26, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (NASDAQ: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Friday March 28, 2025, it will complete a 1-for-27 reverse stock split of its common stock. On September 23, 2024, the Company’s stockholders...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 6, 2025

Lenox Hill Radiology (LHR) in New York and New Jersey Imaging Network (NJIN) to add Nociscan across multiple sites Broomfield, CO, March 06, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Announces First Commercial Agreement with Scripps Health

Mar 3, 2025

Agreement expands access to Nociscan technology for leading spine physicians and more than 3.2M people in the greater San Diego Metro area Nociscan leverages MR Spectroscopy (MRS) and Augmented Intelligence (AI) to Identify Sources of Chronic Low Back Pain Broomfield, CO, March 3, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders

Feb 28, 2025

Meeting adjourned to Wednesday, March 5, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., Feb. 28, 2025 - PRISM MediaWire - Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ: ACON) (NASDAQ: ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Special Meeting of Stockholders (the “Special Meeting”) scheduled for...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion to Showcase Groundbreaking NOCISCAN™ Technology at the 2025 Spine Summit

Feb 20, 2025

Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI) NOCISCAN is an innovative decision support tool that helps physicians personalize treatment for chronic low back pain BROOMFIELD, Colo., February 20, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 11, 2025

Recent Notice of Allowance is for Aclarion’s 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral disc Patent will expand Aclarion’s proprietary rights to use MRS to measure propionic acid as a biomarker for the identification of potential infection and pain throughout the body Broomfield, CO, February 11, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 6, 2025

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 6, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),...